Enzyme therapy for the lysosomal storage disorders: principles, patents, practice and prospects

Bibliography

• KARAGEORGOS LE, ISAAC EL, BROOKS DA et al: Lysosomal biogenesis in lysosomal storage disorders. Exp. Cell Res. (1997) 234(1):85–97.
   PubMedGoogle Scholar
• KOLTER T, DOERING T, WILKENING G, WERTH N, SANDHOFF K: Recent advances in the biochemistry of glycosphingolipid metabolism. Biochem. Soc. Trans. (1999) 27(4):409–415.
   PubMedGoogle Scholar
• WRAITH JE: Lysosomal disorders. &min. Neonatol (2002) 7(1):75–83.
   Google Scholar
• •Excellent general overview of the LSDs, with an emphasis on paediatric presentations.
   Google Scholar
• BEIGHTON G, BEIGHTON P: The person behind the syndrome (revised edn), Springer Verlag, Berlin, Germany (1997).
   Google Scholar
• MEIKLE PJ, HOP WOOD JJ, CLAGUE AE, CAREY WF: Prevalence of lysosomal storage disorders. JAMA (1999) 281:249–254.
   PubMed Web of Science ®Google Scholar
• JEYAKUMAR M, BUTTERS TD, DWEK RA, PLATT FM: Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol AppL NeurobioL (2002) 28(5):343–357.
   PubMedGoogle Scholar
• SCHIFFMANN R, BRADY RO: New prospects for the treatment of lysosomal storage diseases. Drugs (2002) 62 (5) :733–742.
   PubMedGoogle Scholar
• DEDUVE C: From cytases to lysosomes. Fed. Proc. (1964) 23:1045–1049.
   PubMedGoogle Scholar
• BRADY RO: The sphingolipidoses. N Engl. J. Med. (1966) 275(6):312–318.
   PubMedGoogle Scholar
• HOBBS JR, HUGH-JONES K, BARRETT AJ et al.: Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2 (8249) :709–712.
   PubMed Web of Science ®Google Scholar
• RAPPEPORT JM, GINNS El: Bone-marrow transplantation in severe Gaucher's disease. N. Engl. J. Med. (1984) 311(2):84–88.
   PubMed Web of Science ®Google Scholar
• KRIVIT W: Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv. Pediatr. (2002) 49:359–378.
   PubMedGoogle Scholar
• GOODWIN CD: Technology transfer at USuniversities: seeking public benefit from the results of basic research. Technol Health Care. (1996) 4(3):323–330.
   PubMedGoogle Scholar
• HAFFNER ME, WHITLEY J, MOSES M: Two decades of orphan product development. Nat. Rev Drug Discov. (2002) 1(10):821–825.
   PubMedGoogle Scholar
• •Delineates the role of orphan drug legislation in the development of innovative biotechnology products and its impact on public health.
   Google Scholar
• DWEK RA, BUTTERS TD, PLATT FM, ZITZMANN N: Targeting glycosylation as a therapeutic approach. Nat. Rev Drug. Discov (2002) 1(1):65–75.
   PubMed Web of Science ®Google Scholar
• FRUSTACI A, CHIMENTI C, RICCI R et al.: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl. I Med. (2001) 345(1):25–32.
   PubMed Web of Science ®Google Scholar
• KAYE EM, SENA-ESTEVES M: Gene therapy for the central nervous system in the lysosomal storage disorders. Neurol Clin. (2002) 20(3):879–901.
   PubMedGoogle Scholar
• PASTORES GM, BARNETT NL: Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease Type 1. Expert Opin. Investig. Drugs (2003) 12(2):273–281.
   PubMed Web of Science ®Google Scholar
• DESNICK RJ, SCHUCHMAN EH: Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat. Rev. Genet. (2002) 3(12):954–966.
   PubMed Web of Science ®Google Scholar
• BARRANGER JM, NOVELLI EA: Gene therapy for lysosomal storage disorders. Expert Opin. Biol. Ther. (2001) 1(5):857–867.
   PubMedGoogle Scholar
• KAYE EM: Therapeutic approaches to lysosomal storage diseases. Curr. Opin. Pediatr. (1995) 7(6):650–654.
   PubMedGoogle Scholar
• DAMIANO AM, PASTORES GM, WARE JE Jr: The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. QuaL Life Res. (1998) 7(5):373–386.
   PubMed Web of Science ®Google Scholar
• GOLD KF, PASTORES GM, BOTTEMAN MF: Quality of life of patients with Fabry disease. Qual Life Res. (2002) 11(4):317–327.
   PubMedGoogle Scholar
• •Provides a perspective on the burden of disease associated with the LSDs, specifically Fabry disease.
   Google Scholar
• STAHL PD, RODMAN JS, MILLER MJ, SCHLESINGER PH: Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc. Nati Acad. Li. USA (1978) 75(3):1399–1403.
   PubMed Web of Science ®Google Scholar
• STOCKERT RJ, MORELL AG, ASHWELL G: Structural characteristics and regulation of the asialoglycoprotein receptor. Targeted Diagn. Ther. (1991) 4:41–64.
   PubMedGoogle Scholar
• DAHMS NM, HANCOCK MK: P-type lectins. Biochim. Biophys. Acta (2002) 1572(2-3):317–340.
   PubMedGoogle Scholar
• SLY WS: Enzyme replacement therapy: from concept to clinical practice. Acta Paediatr. Suppl. (2002) 91(439):71–78.
   PubMedGoogle Scholar
• BOU-GHARIOS G, ABRAHAM D, OLSEN I: Lysosomal storage diseases: mechanisms of enzyme replacement therapy. Histochem. J. (1993) 25 (9) : 593–605.
   PubMedGoogle Scholar
• KRETZMER G: Industrial processes with animal cells. Appl. Microbiol Biotechnol (2002) 59(2-3):135–142.
   PubMedGoogle Scholar
• SUZUKI K, PROIA RL, SUZUKI K: Mouse models of human lysosomal diseases. Brain Pathol (1998) 8(1):195–215.
   PubMedGoogle Scholar
• SUZUKI K, MANSSON JE: Animal models of lysosomal disease: an overview. J. Inherit. Metab. Dis. (1998) 21(5):540–547.
   PubMedGoogle Scholar
• BOWERS WE, DE DUVE C: Lysosomes in lymphoid tissue. II. Intracellular distribution of acid hydrolases. J. Cell. Biol. (1967) 32(2):339–348.
   PubMedGoogle Scholar
• DE BARSY T, HERS HG: Normal metabolism and disorders of carbohydrate metabolism. Baillieres Clin. Endocrinol Metab. (1990) 4(3):499–522.
   PubMedGoogle Scholar
• BRADY RO: Therapy for the sphingolipidoses. Arch. Neurol (1998) 55(8):1055–1056.
   PubMedGoogle Scholar
• FRATANTONI JC, HALL CW, NEUFELD EF: Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science (1968) 162(853):570–572.
   PubMedGoogle Scholar
• KAPLAN A, FISCHER D, ACHORD D, SLY W: Phosphohexosyl recognition is a general characteristic of pinocytosis of lysosomal glycosidases by human fibroblasts. J. Clin. Invest. (1977) 60(5):1088–1093.
   PubMedGoogle Scholar
• KORNFELD S: Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. AMU. Rev Biochem. (1992) 61:307–330.
   PubMed Web of Science ®Google Scholar
• DESNICK RJ: Enzyme replacement and beyond. J. Inherit. Metab. DAs. (2001) 24(2):251–265.
   PubMed Web of Science ®Google Scholar
• NEUFELD EF: Lysosomal storage diseases. Ann. Rev Biochem. (1991) 60:257–280.
   PubMed Web of Science ®Google Scholar
• LANG L, COUSO R, KORNFELD S: Glycoprotein phosphorylation in simple eucaryotic organisms. Identification of UDP-GlcNAc:glycoprotein N-acetylglucosamine-1-phosphotransferase activity and analysis of substrate specificity. ./. Biol. Chem. (1986) 261(14):6320–6325.
   Google Scholar
• MACH L: Biosynthesis of lysosomal proteases in health and disease. Biol. Chem. (2002) 383(5):751–756.
   PubMedGoogle Scholar
• KRIVIT W, AUBOURG P, SHAPIRO E, PETERS C: Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr. Opin. Hematol. (1999) 6(6):377–382.
   PubMedGoogle Scholar
• KRIVIT W PETERS C, SHAPIRO EG: Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, marmosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease Type III. Cum Opin. Neurol (1999) 12(2):167–176.
   PubMedGoogle Scholar
• DEVINE SM, ADKINS DR, KHOURY H et al.: Recent advances in allogeneic hematopoietic stem-cell transplantation. J. Lab. Clin. Med. (2003) 141(1):7–32.
   PubMedGoogle Scholar
• KAYLER LK, MERION RM, LEES et al: Long-term survival after liver transplantation in children with metabolic disorders. Pediam Transplant. (2002) 6(4):295–300.
   PubMed Web of Science ®Google Scholar
• SESSA A, MERONI M, BATTINI G et al: Renal transplantation in patients with Fabry disease. Nephron. (2002) 91(2):348–351.
   PubMed Web of Science ®Google Scholar
• ARTLETT CM: Microchimerism in health and disease. CUM Mol. Med. (2002) 2(6):525–535.
   PubMedGoogle Scholar
• BRADY RO, BARTON NW: Enzyme replacement therapy for Gaucher disease: critical investigations beyond demonstration of clinical efficacy. Biochem. Med. Metab. Biol. (1994) 52(1):1–9.
   PubMedGoogle Scholar
• TAYLOR ME: Recognition of complex carbohydrates by the macrophage mannose receptor. Biochem. Soc. Trans. (1993) 21(2):468–473.
   PubMedGoogle Scholar
• GEFFEN I, SPIESS M: Asialoglycoprotein receptor. Int. Rev Cytol. (1992) 137B:181–219.
   PubMedGoogle Scholar
• GRABOWSKI GA, BARTON NW, PASTORES G et al: Enzyme therapy in Type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. (1995) 122(1):33–39.
   PubMed Web of Science ®Google Scholar
• FURBISH FS, STEER CJ, KRETT NL, BARRANGER JA: Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim. Biophys. Acta. (1981) 673(4):425–434.
   PubMedGoogle Scholar
• MURRAY GJ, DOEBBER TW, SHEN TY et atTargeting of synthetically glycosylated human placental glucocerebrosidase. Biochem. Med. (1985) 34(2):241–246.
   PubMedGoogle Scholar
• PASTORES GM, SIBILLE AR, GRABOWSKI GA: Enzyme therapy in Gaucher disease Type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood (1993) 82(2):408–416.
   PubMedGoogle Scholar
• DE FOST M, AERTS JM, HOLLAK CE: Gaucher disease: from fundamental research to effective therapeutic interventions. Neth. J. Med. (2003) 61(1):3–8.
   PubMed Web of Science ®Google Scholar
• WEINREB NJ, CHARROW J, ANDERSSON HC et al: Effectiveness of enzyme replacement therapy in 1028 patients with Type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. I Med. (2002) 113(2):112–119.
   Google Scholar
• ELSEA SH, LUCAS RE: The mousetrap: what we can learn when the mouse model does not mimic the human disease. ILAR (2002) 43(2):66–79.
   PubMedGoogle Scholar
• •Instructive review of species-specific differences in certain diseases, including LSDs, between mice and (wo)nen.
   Google Scholar
• WILLEMSEN R, TYBULEWICZ V, SIDRANSKY E et al.: A biochemical and ultrastructural evaluation of the Type 2 Gaucher mouse. Mol. Chem. Neuropathol. (1995) 24(2-3):179–192.
   PubMedGoogle Scholar
• ZHAO H, GRABOWSKI GA: Gaucher disease: perspectives on a prototype lysosomal disease. Cell Mol. Life Sci. (2002) 59(4):694–707.
   PubMed Web of Science ®Google Scholar
• PASTORES GM, THADHANI R: Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin. Biol. Ther. (2002) 2(3):325–333.
   PubMed Web of Science ®Google Scholar
• KAKKIS ED: Enzyme replacement therapyfor the mucopolysaccharide storage disorders. Expert Opin. Investig. Drugs (2002) 11(5):675–685.
   PubMed Web of Science ®Google Scholar
• RABEN N, PLOTZ P, BYRNE BJ: Acid a-glucosidase deficiency (glycogenosis Type II, Pompe disease). Curr. Mol. Med. (2002) 2(2):145–166.
   PubMedGoogle Scholar
• MEIKLE PJ, HOPWOOD JJ, CLAGUE AE, CAREY WF: Prevalence of lysosomal storage disorders. "AMA (1999) 281(3):249–254.
   PubMed Web of Science ®Google Scholar
• The metabolic and molecular basis of inherited diseases (8th edn). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, USA (2001).
   Google Scholar
• SCHIFFMANN R, MURRAY GJ, TRECO D: Infusion of a-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Nati Acad. Li. USA (2000) 97(1):365–370.
   PubMed Web of Science ®Google Scholar
• SCHIFFMANN R, KOPP JB, AUSTIN HA III et al: Enzyme replacement therapy in Fabry disease: a randomised controlled trial. JAMA (2001) 285(21):2743–2749.
   PubMed Web of Science ®Google Scholar
• ENG CM, GUFFON N, WILCOX WR et al: International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human a-galactosidase A-replacement therapy in Fabry's disease. N Engl. J. Med. (2001) 345(1):9–16.
   Google Scholar
• BARTON NW, BRADY RO, DAMBROSIA JM et al: Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Eng. I Med. (1991) 324(21):1464–1470.
   PubMed Web of Science ®Google Scholar
• BROOKS DA: a-L-Iduronidase and enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin. Biol. Ther. (2002) 2(8):967–976.
   PubMed Web of Science ®Google Scholar
• AMALFITANO A, BENGUR AR, MORSE RP et al.: Recombinant human acid a-glucosidase enzyme therapy for infantile glycogen storage disease Type II: results of a Phase I/II clinical trial. Genet. Med. (2001) 3(2):132–138.
   PubMed Web of Science ®Google Scholar
• REUSER AJ, VAN DEN HOUT H, BIJVOET AG, KROOS MA, VERBEET MP, VAN DER PLOEG AT: Enzyme therapy for Pompe disease: from science to industrial enterprise. Eur. I Pediatr. (2002) 161\(Supp1.1):S106–S1011.
   Google Scholar
• DEMETS DL: Clinical trials in the new millennium. Stat. Med. (2002) 21(19):2779–2787.
   PubMedGoogle Scholar
• •Outlines the challenges of research in a global society and the post-genomics era.
   Google Scholar
• FLEMING TR, DEMETS DL: Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. (1996) 125(7):605–613.
   Google Scholar
• BROOKS DA: Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol. Genet. Metab. (1999) 68(2):268–275.
   PubMed Web of Science ®Google Scholar
• RABEN N, JATKAR T, LEE A et al: Glycogen stored in skeletal but not in cardiac muscle in acid a-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther. (2002) 6(5):601–608.
   PubMedGoogle Scholar
• PONCE E, MOSKOVITZ J, GRABOWSKI G: Enzyme therapy in Gaucher disease Type 1: effect of neutralizing antibodies to acid I3-glucosidase. Blood (1997) 90(1):43–48.
   PubMed Web of Science ®Google Scholar
• IOANNOU YA, ZEIDNER KM, GORDON RE, DESNICK RJ: Fabry disease: preclinical studies demonstrate the effectiveness of a-galactosidase A replacement in enzyme-deficient mice. Am. Hum. Genet. (2001) 68(1):14–25.
   PubMed Web of Science ®Google Scholar
• DVIR H, HAREL M, MCCARTHY AA, TOKER L: X-ray structure of human acid-I3-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. (2003) 4(7):1–6.
   Google Scholar
• THURBERG BL, RENNKE H, COLVIN RB et al.: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. (2002) 62(6):1933–1946.
   PubMed Web of Science ®Google Scholar
• PAGANO RE: Endocytic trafficking of glycosphingolipids in sphingolipid storage diseases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2003) 358(1433):885–891.
   PubMedGoogle Scholar
• REID PC, SUGII S, CHANG TY: Trafficking defects in endogenously synthesized cholesterol in fibroblasts, macrophages, hepatocytes, and glial cells from Niemann-Pick type Cl mice. I Lipid Res. (2003) 44(5):1010–1019.
   PubMedGoogle Scholar
• LEE K, JINX, ZHANG K et al: A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology (2003) 13(4) :305–313.
   PubMedGoogle Scholar
• ROSENBERG M, KINGMA W, FITZPATRICK MA, RICHARDS SM: Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood (1999) 93(6):2081–2088.
   PubMed Web of Science ®Google Scholar
• BRADY RO, MURRAY GJ, OLIVER KL: Management of neutralizing antibody to Ceredase in a patient with Type 3 Gaucher disease. Pediatrics (1997) 100(6) :El 1.
   Google Scholar
• VELLODI A, BEMBI B, DE VILLEMEUR TB et al.: Neuronopathic Gaucher disease task force of the european working group on gaucher disease. Management of neuronopathic Gaucher disease: a European consensus. J. Inherit. Metab. Dis. (2001) 24(3):319–327.
   Google Scholar
• JEYAKUMAR M, THOMAS R, ELLIOT-SMITH E et al: Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain (2003) 126(Pt 4):974–987.
   PubMedGoogle Scholar
• •Sheds light on putative mechanisms of cellular injury (e.g., local microgjial activation/expansion and inflammation) triggered by substrate storage, as a possible explanation for the neurodegenerative changes associated with certain LSDs.
   Google Scholar
• MYEROWITZ R, LAWSON D, MIZUKAMI H, MI Y, TIFFT CJ, PROIA RL: Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum. Mol Genet. (2002) 11(10:1343–1350.
   PubMed Web of Science ®Google Scholar
• MIZUKAMI H, MI Y, WADA R et al.: Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J. Clin. Invest. (2002) 9(9):1215–1221.
   Google Scholar
• MOORE DF, HERSCOVITCH P, SCHIFFMANN R: Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J. Neuroimaging (2001) 11(3):303–307.
   PubMed Web of Science ®Google Scholar
• MOORE DF; ALTARESCU A, LING GSF et al.: Cerebrovascular hyperdynamicity in Fabry disease with reversal following enzyme replacement therapy. Stroke (2002) 33(2):525–531.
   Google Scholar
• MOORE DF, SCOTT LT, GLADWIN MT et al.: Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation (2001) 104(13):1506–1512.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM: Targeting neurotherapeutic agents through the blood-brain barrier. Arch. Neurol (2002) 59(1):35–40.
   PubMed Web of Science ®Google Scholar
• ZINBERG RE, KORNREICH R, EDELMANN L, DESNICK RJ: Prenatal genetic screening in the Ashkenazi Jewish population. Clin. Perinatol (2001) 28(2)367–382.
   Google Scholar
• MEIKLE PJ, RANIERI E, RAVENSCROFT EM, HUA CT, BROOKS DA, HOP WOOD JJ: Newborn screening for lysosomal storage disorders. Southeast Asian J. Trop. Med. Public Health (1999) 30\(Supp1.2):104–110.
   Google Scholar
• WALKLEY SU: New proteins from old diseases provide novel insights in cell biology. Curt: Opin. Neurol (2001) 14(6):805–810.
   PubMedGoogle Scholar
• ZERVAS M, SOMERS KL, THRALL MA, WALKLEY SU: Critical role for glycosphingolipids in Niemann-Pick disease type C. Curt: Biol. (2001) 11(16):1283–1287.
   PubMedGoogle Scholar
• MILLAT G, CHIKH K, NAURECKIENE S, SLEAT DE et al: Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. Am. j Hum. Genet. (2001) 69(5):1013–1021.
   PubMedGoogle Scholar
• ANDERSON GE RELNHARDT UE, HUSSEY PS, PETROSYAN V: It's the prices, stupid: why the United States is so different from other countries. Health Aff. (Millwood). (2003) 22(3):89–105.
   PubMedGoogle Scholar
• The World Health Report. World health organisation, Geneva, Switzerland (2002).
   Google Scholar
• YANG W, HAAN K: Strategy: making Genzyme bigger. Biotech. Century (2003) 11(10):2193–2203.
   Google Scholar
• WAGER E: How to dance with porcupines: rules and guidelines on doctors relations with drug companies. Br Med. (2003) 326(7400):1196–1198.
   PubMedGoogle Scholar